- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
CDSCO, State Drugs Control Administration begin joint inspection of drug manufacturing units
![CDSCO, State Drugs Control Administration begin joint inspection of drug manufacturing units CDSCO, State Drugs Control Administration begin joint inspection of drug manufacturing units](https://medicaldialogues.in/h-upload/2022/11/09/750x450_190381-medicine-new-2.webp)
An action plan for nationwide inspection of manufacturing units which are identified to be at risk of manufacturing Not of Standard Quality (NSQ)/adulterated/spurious drugs was made prior to carrying out of inspections.
New Delhi: Under directions of Union Minister of Health & Family Welfare and Chemicals & Fertilizers, Dr. Mansukh Mandaviya, the Central Drugs Standard Control Organisation (CDSCO) has started conducting joint inspection of identified Drug Manufacturing Units along with State Drugs Control Administration as per risk-based approach.
The Joint Inspections are being conducted all over the country as per the Standard Operating Procedures. A committee of two Joint Drugs Controllers has been constituted at CDSCO (HQ) to monitor the process of inspection, reporting & subsequent action so as to ensure compliance to the Drugs & Cosmetics Act, 1940, and Rules thereunder. This will ensure high standards of quality compliance with respect to drugs manufactured in the country.
Read also: Dr Mansukh Mandaviya inaugurates new building of CDSCO Bhawan, South Zone in Chennai
An action plan for nationwide inspection of manufacturing units which are identified to be at risk of manufacturing Not of Standard Quality (NSQ)/adulterated/spurious drugs was made prior to carrying out of inspections.
Read also: CDSCO Panel grants Pfizer's protocol amendment proposal for Tofacitinib
The objective of drug regulation is to ensure safety, efficacy, and quality of the drugs available in the country. The drug control administration is required to ensure that manufacturing units comply with Drugs & Cosmetics Act, 1940 and Rules thereunder especially to the requirements of Good Manufacturing Practices (GMP).
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751